*	OR T5 T6
*	OR T2 T1
R1	Has_qualifier Arg1:T2 Arg2:T3	
R2	AND Arg1:T2 Arg2:T4	
R3	Has_temporal Arg1:T2 Arg2:T5	
R4	Has_negation Arg1:T10 Arg2:T11	
*	OR T9 T12
R5	Has_qualifier Arg1:T27 Arg2:T26	
*	OR T14 T21 T22 T23 T24 T25 T27 T28 T19 T18 T17 T16 T15 T20
R6	Has_qualifier Arg1:T10 Arg2:T9	
R7	Subsumes Arg1:T10 Arg2:T14	
R8	Has_index Arg1:T35 Arg2:T36	
*	OR T33 T34
R9	Has_temporal Arg1:T33 Arg2:T35	
R10	Has_multiplier Arg1:T39 Arg2:T38	
R12	Has_value Arg1:T41 Arg2:T48	
R13	Has_value Arg1:T42 Arg2:T47	
R14	Has_value Arg1:T43 Arg2:T46	
R15	Has_value Arg1:T44 Arg2:T45	
*	OR T41 T43 T42 T44
R11	Subsumes Arg1:T39 Arg2:T41	
R16	Has_temporal Arg1:T39 Arg2:T40	
R17	Has_mood Arg1:T51 Arg2:T54	
R18	Has_mood Arg1:T52 Arg2:T53	
*	OR T51 T52
R19	Has_qualifier Arg1:T58 Arg2:T57	
*	OR T55 T56 T58
R20	Has_temporal Arg1:T55 Arg2:T60	
R21	AND Arg1:T27 Arg2:T20	
R22	AND Arg1:T27 Arg2:T21	
R23	AND Arg1:T27 Arg2:T22	
R24	AND Arg1:T27 Arg2:T23	
R25	AND Arg1:T27 Arg2:T24	
R26	AND Arg1:T27 Arg2:T25	
R27	AND Arg1:T27 Arg2:T28	
T1	Condition 59 70	intolerance
T2	Condition 41 55	adverse events
T3	Qualifier 19 40	medically significant
T4	Drug 76 88	aripiprazole
T5	Temporal 89 112	during screening period
T6	Temporal 116 136	as prior experiences
T9	Qualifier 163 178	DSM-<U+2163>-TR
T10	Condition 205 218	schizophrenia
T11	Negation 194 204	other than
T12	Qualifier 163 167;182 183	DSM- 5
T14	Condition 230 254	schizoaffective disorder
T15	Condition 256 281	major depressive disorder
T16	Condition 283 299	bipolar disorder
T17	Condition 301 309	delirium
T18	Condition 311 319	dementia
T19	Condition 321 328	amnesia
T20	Condition 330 340;432 441	Borderline disorders
T21	Condition 342 350;432 441	Paranoid disorders
T22	Condition 352 362;432 441	Histrionic disorders
T23	Condition 364 375;432 441	Schizotypal disorders
T24	Condition 377 385;432 441	Schizoid disorders
T25	Condition 387 397;432 441	Antisocial disorders
T26	Qualifier 401 406	other
T27	Condition 407 416;432 441	cognitive disorders
T28	Condition 420 441	personality disorders
T32	Post-eligibility 444 584	Subjects with diseases of the central nervous system that may impact the assessment of the psychotic symptoms as per investigator's opinion.
T33	Drug 622 631	clozapine
T34	Drug 635 677	long-acting injectable antipsychotic drugs
T35	Temporal 678 716	within 3 months prior to the screening
T36	Reference_point 703 716	the screening
T38	Multiplier 755 779	maximum maintenance dose
T39	Drug 812 831	oral antipsychotics
T40	Temporal 832 844	at screening
T41	Drug 852 864	Aripiprazole
T42	Drug 875 885	Olanzapine
T43	Drug 896 907	Risperidone
T44	Drug 919 929	Quetiapine
T45	Value 930 941	> 750mg/day
T46	Value 908 917	> 6mg/day
T47	Value 885 894	>20mg/day
T48	Value 864 873	>30mg/day
T51	Observation 980 997	violent behaviour
T52	Condition 1023 1041	committing suicide
T53	Mood 1003 1019	significant risk
T54	Mood 960 976	significant risk
T55	Condition 1114 1122	seizures
T56	Condition 1124 1154	neuroleptic malignant syndrome
T57	Qualifier 1156 1178	clinically significant
T58	Condition 1179 1197	tardive dyskinesia
T59	Non-representable 1199 1298	or other medical condition that would expose them to undue risk or interfere with study assessments
T60	Temporal 1103 1110	history
T62	Intoxication_considerations 1301 1490	Significant history of drug abuse disorder (including alcohol, as defined in DSM-5 substance use disorder or in the opinion of the investigator) within the last 6 months prior to screening.
T63	Competing_trial 1492 1587	Subjects participating another interventional clinical trial within 30 days prior to screening.
T64	Pregnancy_considerations 1589 1672	Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
T65	Post-eligibility 1674 1871	Subjects having any other clinically significant finding of the physical examination or laboratory value that make investigator consider that it would be inappropriate to participate in this study.
